Tutorial in Biostatistics
Sample sizes for clinical trials with Normal data
Steven A. Julious,
Corresponding Author
Steven A. Julious
Institute of General Practice and Community Care, Community Science Centre, Northern General Hospital, Herries Road, Sheffield, S5 7AU, U.K.
Medical Statistics Unit, Institute of General Practice and Community Care, Community Science Centre, Northern General Hospital, Herries Road, Sheffield, S5 7AU, U.K.Search for more papers by this authorSteven A. Julious,
Corresponding Author
Steven A. Julious
Institute of General Practice and Community Care, Community Science Centre, Northern General Hospital, Herries Road, Sheffield, S5 7AU, U.K.
Medical Statistics Unit, Institute of General Practice and Community Care, Community Science Centre, Northern General Hospital, Herries Road, Sheffield, S5 7AU, U.K.Search for more papers by this authorAbstract
This article gives an overview of sample size calculations for parallel group and cross-over studies with Normal data. Sample size derivation is given for trials where the objective is to demonstrate: superiority, equivalence, non-inferiority, bioequivalence and estimation to a given precision, for different types I and II errors. It is demonstrated how the different trial objectives influence the null and alternative hypotheses of the trials and how these hypotheses influence the calculations. Sample size tables for the different types of trials and worked examples are given. Copyright © 2004 John Wiley & Sons, Ltd.
REFERENCES
- 1 Medical Research Council. Streptomycin treatment of pulmonary tuberculosis. British Medical Journal 1948; 2: 769–782.
- 2 Julious SA, Zariffa N. The ABC of pharmaceutical trial design: some basic principles. The Journal of Pharmaceutical Statistic 2002; 1: 45–53.
10.1002/pst.6 Google Scholar
- 3 ICH E9. Statistical principals for clinical trials. September 1998. http://www.fda.gov/cder/guidance/ICH_E9-fnl.PDF [last accessed 23 October 2003].
- 4 Altman DG, Bland JM. Treatment allocation in controlled trials: why randomize? British Medical Journal 1999; 318: 1209.
- 5 Day S. Blinding or masking. In Encyclopedia of Biostatistics, vol. 1, P Armitage, T Colton (eds). John Wiley and Sons: Chichester, 1998; 410–417.
- 6 Altman DG. Statistics and ethics in medical research III—how large a sample? British Medical Journal 1980; 281: 1336–1138.
- 7 ICH E3. Structure and content of clinical study reports. July 1996. http://www.fda.gov/cder/guidance/iche3.pdf [last accessed 23 October 2003].
- 8 Hintz JL. PASS 2000 User's Guide. Kaysville, 2000.
- 9 Elashoff JD. nQuery advisor version 4 user's guide. Los Angeles, 2000.
- 10 Julious SA, Campbell MJ, Altman DG. Estimating sample sizes for continuous, binary and ordinal outcomes in paired comparisons: practical hints. Journal of Biopharmaceutical Statistics 1999; 9(2): 241–251.
- 11 Campbell MJ, Julious SA, Altman DG. Estimating sample sizes for binary, ordered categorical, and continuous outcomes in two group comparisons. British Medical Journal 1995; 311: 1145–1148.
- 12 Donner A. Approaches to sample size estimation in the design of clinical trials—a review. Statistics in Medicine 1983; 3: 199–214.
- 13 Machin D, Campbell MJ, Fayers P, Pinol A. Statistical Tables for the Design of Clinical Studies ( 2nd edn). Blackwell Scientific Publications: Oxford, 1997.
- 14 Koch GG, Gansky SA. Statistical considerations for multiplicity in confirmatory trials. Drug Information Journal 1996; 30: 523–534.
10.1177/009286159603000228 Google Scholar
- 15 CPMP. Points to consider on multiplicity issues in clinical trials. (CPMP/EWP/908/99) 19 September 2002 http://www.emea.eu.int/pdfs/human/ewp/090899en.pdf (last accessed 21 October 2003 ).
- 16 Gould AL. Interim analyses for monitoring clinical trials that do not materially effect the type I error rate. Statistics in Medicine 1992; 11: 55–66.
- 17 Gould AL. Planning and revising the sample size for a trial. Statistics in Medicine 1995; 14: 1039–1051.
- 18 Zucker DM, Denne J. Sample size re-determination for repeated measures studies. Biometrics 2002; 48(3): 548–559.
- 19 Zucker DM, Wittes JT, Schabenberger O, Brittain E. Internal pilot studies II. Comparison of various procedures. Statistics in Medicine 1999; 18: 3493–3509.
10.1002/(SICI)1097-0258(19991230)18:24<3493::AID-SIM302>3.0.CO;2-2 CAS PubMed Web of Science® Google Scholar
- 20 Gould AL, Shih WJ. Sample size re-estimation without unblinding for normally distributed data with unknown variance. Communications in Statistics—Theory and Methods 1992; 21: 2833–2853.
- 21 Gould AL, Shih WJ. Modifying the design of ongoing trials without unblinding. Statistics in Medicine 1998; 17: 89–100.
10.1002/(SICI)1097-0258(19980115)17:1<89::AID-SIM730>3.0.CO;2-D CAS PubMed Web of Science® Google Scholar
- 22 Birkett MA, Day SJ. Internal Pilot studies for estimating sample size. Statistics in Medicine 1994; 13: 2455–2463.
- 23 Kieser M, Friede T. Re-calculating the sample size in internal pilot study designs with control of the type I error rate. Statistics in Medicine 2000; 19: 901–911.
10.1002/(SICI)1097-0258(20000415)19:7<901::AID-SIM405>3.0.CO;2-L CAS PubMed Web of Science® Google Scholar
- 24 Wittes J, Brittain E. The role of internal pilot studies in increasing the efficacy of clinical trials. Statistics in Medicine 1990; 9: 65–72.
- 25 Neyman J, Pearson ES. On the use and interpretation of test criteria. Biometrika 1928; 20(A): 175–194.
- 26 Neyman J, Pearson ES. On the problem of the most efficient tests of statistical hypotheses. Philosophical Transitions Royal Society (London) 1933; 23: 289–237.
- 27 Neyman J, Pearson ES. The testing of statistical hypotheses in relation to the probabilities a priori. Proceeds of the Cambridge Philosophical Society 1933; 29: 492–510.
- 28 Neyman J, Pearson ES. Contributions to the theory of testing hypotheses. Journal Statistical Research Memoirs (University of London) 1936; 1: 1–37.
- 29 Neyman J, Pearson ES. Sufficient statistics and uniformly most powerful test of statistical hypothesis. Journal Statistical Research Memoirs (University of London) 1936; 1: 113–137.
- 30 Neyman J, Pearson ES. Contributions to the theory of testing statistical hypotheses. Journal Statistical Research Memoirs (University of London) 1938; 2: 25–57.
- 31 Fayers P, Machin D. Sample size: how many patients are necessary? British Journal of Cancer 1995; 72: 1–9.
- 32 Armitage P, Berry G. Statistical Methods in Medical Research ( 3rd edn). Blackwell Science: Oxford.
- 33 Schouten HJA. Sample size formula with a continuous outcome for unequal group sizes and unequal variances. Statistics in Medicine 1999; 18: 87–91.
10.1002/(SICI)1097-0258(19990115)18:1<87::AID-SIM958>3.0.CO;2-K CAS PubMed Web of Science® Google Scholar
- 34 Singer J. A simple procedure to compute sample size needed to compared two independent groups when the population variances are unknown. Statistics in Medicine 2001; 20: 1995.
- 35 Brush GG. How to choose the proper sample size, vol. 12, The ASQC Basic References in Quality Control, Statistical Techniques, American Society for Quality Control: Milwaukee, WI, 1988.
- 36 Senn S. Cross-over Trials in Clinical Research. John Wiley and Sons: Chichester, 1993.
- 37 Chow SC, Shao J, Wang H. A note on sample size calculations for mean comparisons based on noncentral t-statistics. Journal of Pharmaceutical Statistics 2002; 12: 441–456.
- 38 Guenther WC. Sample size formulas for normal theory t-tests. The American Statistician 1981; 35: 243–244.
- 39 Berger RL, Hsu, JC. Bioequivalence trials, intersection-union tests and equivalence confidence sets. Statistical Science 1996; 11: 283–319.
- 40 Jones B, Jarvis P, Lewis JA, Ebbutt AF. Trials to assess equivalence: the importance of rigorous methods. British Medical Journal 1996; 313: 36–39.
- 41 ICH E10 Choice of control group in clinical trials, 2000. May 2001 http://www.fda.gov/cder/guidance/4155fnl.pdf (last accessed 10 November 2003).
- 42 CPMP. Points to consider on switching between superiority and non-inferiority. (CPMP/EWP/482/99) 17 July 2000. http://www.emea.eu.int/pdfs/human/ewp/048299en.pdf (last accessed 21 October 2003).
- 43 CPMP. Concept paper on the development of a committee for proprietary medicinal products (CPMP) points to consider on biostatistical methodological issues arising from recent CPMP discussions on licensing applications: choice of delta. (CPMP/EWP/2158/99) 23 September 1999. http://www.emea.eu.int/ pdfs/human/ewp/215899en.pdf (last accessed 21 October 2003).
- 44 Hung HMJ, Wang SJ, Lawrence J, O'Neil RT. Some fundamental issues with non-inferiority testing in active controlled trials. Statistics in Medicine 2003; 22: 213–225.
- 45 D'Agostino RB, Massaro J, Sullivan LM. Non-inferiority trials: design concepts and issues—the encounters of academic consultants in statistics. Statistics in Medicine 2003; 22: 169–186.
- 46 Wiens BL. Choosing an equivalence limit for noninferiority and or equivalence studies. Controlled Clinical Trials 2002; 23: 2–14.
- 47 Owen DB. A special case of a bivariate non-central t-distribution. Biometrika 1965; 52: 437–446.
- 48 Diletti E Hauschke D, Steinijans VW. Sample size determination form bioequivalence assessment by means of confidence intervals. International Journal of Clinical Pharmacology, Therapy and Toxicology 1991; 29: 1–8.
- 49 Morikawa T, Yoshida M. A useful testing strategy in phase III trials: combined test of superiority and test of equivalence. Journal of Biopharmaceutical Statistics 1995; 5(3): 297–306.
- 50 Senn S. In the blood: proposed new requirements for the registering of generic drugs. The Lancet 1998; 352: 85–86.
- 51 FDA. Guidance for industry. Bioavailability and bioequivalence studies for orally administered drug products—general considerations. October 2000. http://www.fda.gov/cder/guidance/3615fnl.pdf (last accessed 23 October 2003).
- 52 FDA. Statistical approaches to establishing bioequivalence. January 2001. http://www.fda.gov/cder/guidance/3616fnl.pdf (last accessed 23 October 2003).
- 53 CPMP. Note for guidance on the investigation of bioavailability and bioequivalence. (CPMP/EWP/QWP1401/98) 26 July 2001. http://www.emea.eu.int/pdfs/human/ewp/140198en.pdf (last accessed 21 October 2003).
- 54 FDA. Guidance for industry. Food-effect bioavailability and fed bioequivalence studies. December 2000. http://www.fda.gov/cder/guidance/5194fnl.pdf (last accessed 23 October 03).
- 55 CPMP. Note for guidance on the investigation of drug interactions. (CPMP/EWP/560/95) 17 December 1997. http://www.emea.eu.int/pdfs/human/ewp/056095en.pdf (last accessed 21 October 2003).
- 56 FDA. Guidance for industry. In vivo drug metabolism/drug interaction studies—study design, data analysis, and recommendations for dosing and labelling. November 1999. http://www.fda.gov/cder/guidance/2635fnl.pdf (last accessed 23 October 2003).
- 57 FDA. Guidance for industry. Pharmacokinetics in patients with impaired renal function—study design, data analysis and impact on dosing and labelling. May 1998. http://www.fda.gov/cder/guidance/1449fnl.pdf pdf (last accessed 23 October 2003).
- 58 FDA. Guidance for industry. Pharmacokinetics in patients with impaired hepatic function: study design, data analysis and impact on dosing and labelling. May 2003. http://www.fda.gov/cder/guidance/3625fnl.pdf (last accessed 23 October 2003).
- 59 Julious SA, Debarnot CAM. Why are pharmacokinetic data summarized as arithmetic means. Journal of Biopharmaceutical Statistics 2000; 10(1): 55–71.
- 60 Lacey JM, Keene ON, Pritchard JF, Bye A. Common non-compartmental pharmacokinetic variables: are they normally or log-normally distributed? Journal of Biopharmaceutical Statistics 1997; 7(1): 171–178.
- 61 Liu JP. Use of the repeated cross-over designs in assessing bioequivalence. Statistics in Medicine 1995; 14: 1067–1078.
- 62 Whitehead A, Whitehead J. A general parametric approach to the meta-analysis of randomized trials. Statistics in Medicine 1991; 10: 1665–1677.
- 63 Schall R, Williams RL. Towards a practical strategy for assessing individual bioequivalence. Journal of Pharmacokinetics and Biopharmaceutics 1996; 24: 133–149.
- 64 Hauck WW, Anderson S. Types of bioequivalence and related statistical considerations. International Journal of Clinical Pharmacology, Therapy and Toxicology 1992; 30: 181–187.
- 65 Day S. Clinical trial numbers and confidence intervals of pre-specified size. The Lancet 1988; 17: 1427.
10.1016/S0140-6736(88)90620-4 Google Scholar
- 66 Wood J, Lambert M. Sample-size calculations for trials in health services research. Journal of Health Services and Research and Policy 1999; 4: 226–229.
- 67 Desu MM, Raghavarao D. Sample Size Methodology. Academic Press: London, 1990.
- 68 CPMP. Points to consider on adjustment for baseline covariates. (CPMP/EWP/2863/99) 23 May 2003. http://www.emea.eu.int/pdfs/human/ewp/286399en.pdf (last accessed 21 October 2003).
- 69 Frison LJ, Pocock SJ. Repeated measures in clinical trials: analysis using mean summary statistics and its implication for design. Statistics in Medicine 1992; 11: 1685–1704.
- 70 Diggle PJ, Liang KY, Zeger SL. Analysis of Longitudinal Data. Oxford University Press: Oxford, 1996.
- 71 Julious SA. Repeated measures in clinical trials: analysis using means summary statistics and its implications for design. Statistics in Medicine 2000; 19: 3133–3135.
10.1002/1097-0258(20001130)19:22<3133::AID-SIM744>3.0.CO;2-0 CAS PubMed Web of Science® Google Scholar
